ArticleBiochemistry and biophysics reports2026
Monocyte chemoattractant protein-1 (MCP-1/CCL2) and matrix metalloproteinase-9 (MMP-9) as biomarkers of disease severity in COVID-19 patients.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Monocyte chemoattractant protein 1 (MCP1/CCL2) and matrix metalloproteinase (MMP9) in COVID-19 Patients are key immune elements that may be involved in COVID-19-induced cytokine storm. Methods: We recruited patients in three patient groups, outpatient, hospitalized, and critical ICU COVID-19 cases as well as a group consisting of healthy controls. Venous blood was collected. Following the separation of peripheral blood mononuclear cells (PBMCs) which comprise various immune cells, total RNA extraction and cDNA generation were conducted. RT-PCR was achieved by primers exclusively designed for MMP9 and CCL2. Results: For both MMP9 and CCL2 highest expression was found in PBMCs from critical COVID-19 cases. Interestingly, a J-shaped pattern of expression was found for both genes. Conclusion: MMP9 and CCL2 could be a potential clinical biomarker for patients with COVID-19. Regulation of these immune elements may be complex and responsible mechanisms deserve further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.